Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention

JACC: Cardiovascular Interventions

Volumn 4, Issue 2, 2011, Pages 191-197

  Verheugt, Freek W A ^a,b   Steinhubl, Steven R ^c   Hamon, Martial ^d   Darius, Harald ^e   Steg, Philippe Gabriel ^f   Valgimigli, Marco ^g   Marso, Steven P ^h   Rao, Sunil V ⁱ   Gershlick, Anthony H ^j   Lincoff, A Michael ^k   Mehran, Roxana ^l   Stone, Gregg W ^l  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^c GEISINGER MEDICAL CENTER   (United States)

^d CAEN UNIVERSITY HOSPITAL   (France)

^e VIVANTES KLINIKUM NEUKÖLLN   (Germany)

^f INSERM   (France)

^g UNIVERSITY OF FERRARA   (Italy)

^h SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

ⁱ DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^j UNIVERSITY OF LEICESTER   (United Kingdom)

^k LERNER RESEARCH INSTITUTE   (United States)

^l Howard Hughes Medical Institute   (United States)

more..

Author keywords

access site; bivalirudin; bleeding; percutaneous coronary intervention; Thrombolysis In Myocardial Infarction (TIMI)

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; DISEASE ASSOCIATION; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; VASCULAR ACCESS;

AGED; ANGIOPLASTY, BALLOON, CORONARY; ANTICOAGULANTS; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN; HIRUDINS; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROPORTIONAL HAZARDS MODELS; PUNCTURES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 79951970832     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2010.10.011     Document Type: Article

References (17)

1. R. Mehran, S.J. Pocock, and G.W. Stone Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial Eur Heart J 30 2009 1457 1466
2. A. Budaj, J.W. Eikelboom, and S.R. Mehta Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes Eur Heart J 30 2009 655 661
3. S.S. Jolly, S. Amlani, M. Hamon, S. Yusuf, and S.R. Mehta Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: a systematic review and meta-analysis of randomized trials Am Heart J 157 2009 132 140
4. A. Kastrati, F.J. Neumann, and J. Mehilli Bivalirudin versus unfractionated heparin during percutaneous coronary intervention N Engl J Med 359 2008 688 696
5. A.M. Lincoff, J.A. Bittl, and R.A. Harrington Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial JAMA 289 2003 853 863 (Pubitemid 37430344)
6. G.W. Stone, B.T. McLaurin, and D.A. Cox Bivalirudin for patients with acute coronary syndromes N Engl J Med 355 2006 2203 2216 (Pubitemid 44791162)
7. G.W. Stone, B. Witzenbichler, and G. Guagliumi Bivalirudin during primary PCI in acute myocardial infarction N Engl J Med 358 2008 2218 2230 (Pubitemid 351724451)
8. B.J. Doyle, C.S. Rihal, D.A. Gastineau, and D.R. Holmes Jr Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice J Am Coll Cardiol 53 2009 2019 2027
9. E.F. Ewen, L. Zhao, and P. Kolm Determining the in-hospital cost of bleeding in patients undergoing percutaneous coronary intervention J Interv Cardiol 22 2009 266 273
10. M. Hamon, and G. Coutance Transradial intervention for minimizing bleeding complications in percutaneous coronary intervention Am J Cardiol 104 2009 55C 59C
11. G. Montalescot, H.D. White, and R. Gallo Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention N Engl J Med 355 2006 1006 1017 (Pubitemid 44343544)
12. S. Yusuf, S.R. Mehta, and S. Chrolavicius Comparison of fondaparinux and enoxaparin in acute coronary syndromes N Engl J Med 354 2006 1464 1476
13. R. Mehran, A.J. Lansky, and B. Witzenbichler Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial Lancet 374 2009 1149 1159
14. G. Maluenda, G. Lemesle, and S.D. Collins The clinical significance of hematocrit values before and after percutaneous coronary intervention Am Heart J 158 2009 1024 1030
15. M.D. Voeltz, A.D. Patel, F. Feit, R. Fazel, A.M. Lincoff, and S.V. Manoukian Effect of anemia on hemorrhagic complications and mortality following percutaneous coronary intervention Am J Cardiol 99 2007 1513 1517 (Pubitemid 46770636)
16. J.P. Bassand, R. Afzal, and J. Eikelboom Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes Eur Heart J 31 2010 50 58
17. G. Montalescot, G. Cayla, and J.P. Collet Immediate vs delayed intervention for acute coronary syndromes: a randomized clinical trial JAMA 302 2009 947 954